MedTrace Logo

Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy

NCT03005769 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2017-07-19

No results posted yet for this study

Summary

This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data collection starts (inclusion visit), and is designed to evaluate demographic and clinical predictors of persistence with this treatment.

Data from each patient will be collected after informed consent is signed (inclusion visit), and will include retrospective information from the start of aripiprazole once-monthly treatment initiation (index date) until the follow-up/inclusion visit (minimum of 6 months after the index date). Data will be retrospectively collected from all visits occurring as per clinical practice (usually once monthly).

Conditions

Sponsors & Collaborators

  • Otsuka Pharmaceutical Europe Ltd

    lead INDUSTRY

Principal Investigators

  • Medical Department · Otsuka Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03005769 on ClinicalTrials.gov